Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.76 |
| ▸ | DRD3 | P35462 | 2/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | GHSR | Q92847 | 2/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | HTR3A | P46098 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desalkylflurazepam SCHEMBL31365163 | 1.00 | OPRK1 (0.76) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11679711 | 0.90 | OPRK1 (0.74) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL9746460 | 0.88 | OPRK1 (0.81) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL7433919 | 0.88 | OPRK1 (0.77) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL17378494 | 0.87 | OPRK1 (0.71) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11851286 | 0.87 | OPRK1 (0.74) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11577314 | 0.87 | OPRK1 (0.74) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL10587083 | 0.86 | OPRK1 (1.00) | OPRK1DRD3KCNH2GHSRHTR1A | |
| Flurazepam SCHEMBL29793 | 0.86 | OPRK1 (1.00) | OPRK1DRD3KCNH2GHSRHTR1A | |
| SCHEMBL11579759 | 0.86 | OPRK1 (0.72) | OPRK1DRD3KCNH2GHSRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-20250281926-A1 | SAMPLE MANIPULATION AND ASSAY WITH RAPID TEMPERATURE CHANGE | ESSENLIX CORPORATION (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250099965-A1 | RAPID SAMPLE TEMPERATURE CHANGING FOR ASSAYING | ESSENLIX CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226769-B2 | Sample manipulation and assay with rapid temperature change | ESSENLIX CORPORATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12064771-B2 | Rapid sample temperature changing for assaying | ESSENLIX CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-11796428-B2 | Compressed open flow assay and use | ESSENLIX CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11648551-B2 | Sample manipulation and assay with rapid temperature change | ESSENLIX CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230093302-A1 | A NOVEL MAO-B INHIBITOR DRG-MAOB-1 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | BAHCESEHIR UNIVERSITESI (TR) | 2023-03-23 | — | — | US | disclosed |
| US-20230088611-A1 | A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | ISTANBUL GEDIK UNIVERSITESI | 2023-03-23 | — | — | US | disclosed |
| US-20220236149-A1 | COMPRESSED OPEN FLOW ASSAY AND USE | ESSENLIX CORPORATION (US) | 2022-07-28 | — | — | US | disclosed |
| US-11274996-B2 | Compressed open flow assay and use | ESSENLIX CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2019215426-A1 | PROCESS FOR FORMING A CARBON-CARBON BOND | THE UNIVERSITY OF MANCHESTER (GB) | 2019-11-14 | — | — | WO | disclosed |
| EP-0635016-B1 | BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE CONJUGATES THEREOF | BIOSITE DIAGNOSTICS INC (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5618926-A | Immunoassay reagents | HOFFMANN-LA ROCHE INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0635016-A4 | BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE CONJUGATES THEREOF. | BIOSITE DIAGNOSTICS INC (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0635016-A1 | BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE CONJUGATES THEREOF | BIOSITE DIAGNOSTICS INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5302715-A | Benzodiazepine derivatives | BIOSITE DIAGNOSTICS, INC. (US) | 1994-04-12 | — | — | US | disclosed |
| WO-1993020067-A1 | BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE CONJUGATES THEREOF | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1993-10-14 | — | — | WO | disclosed |
| US-4656026-A | DIAGNOSING MENTAL, MOVEMENT, SEIZURE DISORDERS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1987-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | OPRK1 13/4885DRD3 1215/4885KCNH2 3831/4885 |
| US-20230088611-A1 | A NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | MAOB, MAOA, HTR2B | OPRK1 8/4885DRD3 747/4885KCNH2 2569/4885 |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | MAOB, MAOA, HTR2B | OPRK1 7/4885DRD3 691/4885KCNH2 2908/4885 |
| US-20230093302-A1 | A NOVEL MAO-B INHIBITOR DRG-MAOB-1 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | MAOB, MAOA, HTR1B | OPRK1 6/4885DRD3 670/4885KCNH2 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.